Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Muscle Growth
Truncated IGF-1 variant — site-specific, short-acting muscle growth signal.
Peptide B
Muscle Growth
Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling.
Typical vial
1 mg
Typical dose
20-100 mcg
Half-life
~20-30 minutes
FDA status
Not FDA approved.
Typical vial
1 mg
Typical dose
20-50 mcg
Half-life
~20-30 hours
FDA status
Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Inc…
IGF-1 DES effects
IGF-1 LR3 effects
IGF-1 DES side effects
IGF-1 LR3 side effects
IGF-1 DES dosing ranges
Site-specific muscle hypertrophy
20-50 mcg per site · Into trained muscle post-workout (IM) · 30-50 days per cycle
General anabolic support
50-100 mcg · Once daily (SubQ) · 30-50 days per cycle
IGF-1 LR3 dosing ranges
Research / muscle hypertrophy
20-50 mcg · Once daily (SubQ or IM), pre- or post-workout · 30-50 days per cycle
Site-specific injection (research)
20-40 mcg per site · Into trained muscle, post-workout · 30-50 days per cycle
IGF-1 DES: Truncated IGF-1 variant — site-specific, short-acting muscle growth signal. Typical dose 20-100 mcg. IGF-1 LR3: Long-acting IGF-1 analog with reduced binding-protein affinity for sustained signaling. Typical dose 20-50 mcg. Both fall under the Muscle Growth category.
Stacking IGF-1 DES with IGF-1 LR3 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
IGF-1 DES is typically dosed: Into trained muscle post-workout (IM) for Site-specific muscle hypertrophy; Once daily (SubQ) for General anabolic support. IGF-1 LR3 is typically dosed: Once daily (SubQ or IM), pre- or post-workout for Research / muscle hypertrophy; Into trained muscle, post-workout for Site-specific injection (research).
IGF-1 DES: Not FDA approved. IGF-1 LR3: Not FDA approved. Native recombinant rhIGF-1 (mecasermin/Increlex) is FDA approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 itself is not.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free